Surfactant protein B gene variations enhance susceptibility to squamous cell carcinoma of the lung in German patients by Seifart, C et al.
Surfactant protein B gene variations enhance susceptibility to
squamous cell carcinoma of the lung in German patients
C Seifart*
,1, U Seifart
2, A Plagens
1, M Wolf
2 and P von Wichert
1
1Department of Internal Medicine, Division of Respiratory and Critical Care Medicine, Philipps-University of Marburg, Baldingerstraße, 35043 Marburg,
Germany;
2Department of Internal Medicine, Division of Oncology and Hematology Philipps-University of Marburg, Baldingerstraße, 35043 Marburg, Germany
Genetic factors are thought to inﬂuence the risk for lung cancer. Since pulmonary surfactant mediates the response to inhaled
carcinogenic substances, candidate genes may be among those coding for pulmonary surfactant proteins. In the present
matched case–control study a polymorphism within intron 4 of the gene coding for surfactant speciﬁc protein B was analysed
in 357 individuals. They were divided into 117 patients with lung cancer (40 patients with small cell lung cancer, 77 patients
with non small cell lung cancer), matched controls and 123 healthy individuals. Surfactant protein B gene variants were
analysed using speciﬁc PCR and cloned surfactant protein B sequences as controls. The frequency of the intron 4 variation was
similar in both control groups (13.0% and 9.4%), whereas it was increased in the small cell lung cancer group (17.5%) and the
non small cell lung cancer group (16.9%). The gene variation was found signiﬁcantly more frequently in patients with squamous
cell carcinoma (25.0%, P=0.016, odds ratio=3.2, 95%CI=1.24–8.28) than in the controls. These results indicate an association
of the surfactant protein B intron 4 variants and/or its ﬂanking loci with mechanisms that may enhance lung cancer
susceptibility, especially to squamous cell carcinoma of the lung.
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Individual cancer risk is due to gene-environmental interaction.
Exposure to exogenous carcinogens, such as tobacco smoke is
clearly related to the development of lung cancer. However, genetic
factors may strongly mediate the risk among those who are
exposed to carcinogens, as only 11% of the tobacco smokers ulti-
mately develop lung cancer (Amos et al, 1999). In patients with
impaired lung function, incidence and mortality of lung cancer is
increased, independent of smoking habits, age and family history
(Skillrud et al, 1986). Thus, in response to environmental mutagens
the individual variability may be mediated by local factors of the
airways.
The pulmonary surfactant system is essential for normal lung
function and play an important role in mediating local airway
condition. Pulmonary surfactant is a complex mixture of lipids,
primarily phospholipids, and surfactant speciﬁc proteins. Structure
and homeostasis of the system depends on the surfactant speciﬁc
proteins SP-A, B and C. Next to surface tension lowering proper-
ties at the air/liquid interface, a number of additional functions
have been attributed to the surfactant system. A bronchiolar surfac-
tant layer has been demonstrated (Morgenroth, 1985) that appears
to be important for several physiological functions of the airways.
It improves bronchiolar mucociliary clearance, encoates inhaled
particles and substances and is involved in their clearance from
the upper respiratory tract (Gehr et al, 1993; De Sanctis et al,
1994). Because of the importance of surfactant in normal lung
function, in mediating local airway conditions and in the clearance
of the upper respiratory tract, surfactant protein genes may be
good candidates in the study of etiologic factors for lung cancer.
Surfactant protein B is important for the formation of the active
surfactant surface ﬁlm (Schu ¨rch et al, 1998) and is essential for
normal lung function (Robertson et al, 1991). Surfactant protein
B knock out mice show disruption of surfactant ﬁlm and function
and die from respiratory failure (Clark et al, 1995, 1997). Further-
more, these mice are more susceptible to oxidative lung injury
(Tokieda et al, 1999).
The gene for SP-B has been localized on the short arm of chro-
mosome 2 (Emrie et al, 1988; Vamvakopoulos et al, 1995),
consisting of 11 exons with the ﬁrst 10 encoding the precursor
protein. Different polymorphisms within the SP-B gene have been
described (Pilot-Matias et al, 1989; Nogee et al, 1994; Floros et al,
1995; Lin et al, 1998, 1999a) and SP-B gene variations have been
associated with several diseases, such as respiratory distress
syndrome (RDS) (Floros et al, 1995), COPD (Seifart et al, 2002)
and congenital alveolar proteinosis (Nogee et al, 1994; Lin et al,
1998). Recently, an aberrantly spliced SP-B mRNA had been asso-
ciated with lung disease (Lin et al, 1999a).
Genetic factors are important in the development of lung cancer
and pulmonary surfactant may be involved in mechanisms that
enhance cancer susceptibility in the lung. Therefore, we hypothe-
sised that surfactant protein gene variants may be related to an
increased risk for developing lung cancer. Because SP-B is essential
for spreading of surfactant, we analysed a large gene variation with-
in intron 4 of the surfactant protein B gene in a case–control
study in patients with small cell lung cancer (SCLC) and non small
lung cancer (NSCLC), their matched control and healthy indivi-
duals.
The data revealed an enhanced frequency of intron 4 variants in
the disease groups, and a signiﬁcantly higher frequency in the squa-
mous cell carcinoma group, suggesting an association between the
SP-B locus and/or its ﬂanking loci and lung cancer susceptibility.
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Patients
We studied the frequency of a variant locus within intron 4 of the
gene coding for the surfactant speciﬁc protein B in 357 Caucasian
individuals. These were divided into two patient groups (non small
cell lung cancer and small cell lung cancer), their matched controls
and 123 healthy individuals. All patients suffering from lung cancer,
who were treated between January 1999 and December 1999 in the
Department of Oncology were included. A standard questionnaire
was used to obtain information about smoking, age, and case
history. To set up the matched pairs, from a total of 600 patients
undergoing lung function testing in the Department of Internal
Medicine those without pulmonary disease, matching age, gender
and smoking habits were included. Of the 117 patients with lung
cancer, 77 suffered from non small cell lung cancer (NSCLC) and
40 patients from small cell lung cancer (SCLC). Ten pack years
(p/y) were used as cut-off for smoking classiﬁcation, because a
signiﬁcant excess risk of 70% has been associated with every 10 pack
years in a European multicentre study (Agudo et al, 2000). Smoking
habits were classiﬁed as follows: (a) never smokers and ever smokers,
who had smoked at least 100 cigarettes in his or her life time, but
smoked less than 10 pack years, were classiﬁed as light smokers
(b) former smokers stopped smoking at least 1 year before inclusion
into the study, but smoked more than 10 pack years, were classiﬁed
as former smokers and (c) current smokers smoked more than 10
pack years were classiﬁed as current smokers. Calculation of exact
pack years were done for the former and current smokers of the lung
cancer groups. The characteristics of the groups are summarised in
Table 1A and B, and described below. Blood specimens were drawn
for genotype analysis with informed consent of the patients.
Population group
This group consisted of 123 healthy individuals. These individuals
got physical examination by the staff medical service at the Univer-
sity of Marburg upon entering a new position or changing
positions between October 1998 and July 1999. Age of the 123
individuals, 62 males and 61 females, ranged from 20 to 62 years.
Forty-ﬁve (36.6%) individuals were classiﬁed as current smokers,
nine (7.3%) as former smokers and 69 (56.1%) were never smokers
or ever smokers smoked less than 10 pack years. Because the popu-
lation control should represent a group comparable to the normal
population the cases came from, the individuals are not age, smok-
ing-habits, and gender matched. Therefore, the control population
has a younger age than the patients and their matched controls.
NSCLC-group
The NSCLC-group consisted of 77 patients with non small cell
lung cancer, including 40 patients with squamous cell carcinoma
(SCC), 26 with adenocarcinoma, ﬁve with large cell carcinoma
and six with other tumour histology. As is typical of lung cancer,
the group consisted of 69 males and eight females (gender-ratio:
8.6), with mean age 65.4 (42–82 years). Out of 77 patients, nine
(11.7%) were never or light smokers, 11 (14.3%) were former
smokers, while 57 (74.0%) were current smokers (Table 1A,B).
Six patients with adenocarcinoma, two with squamous cell carcino-
ma and one with undifferentiated carcinoma were classiﬁed as light
smokers. Ten patients had not smoked more than 20 p/y (12.9%),
25 patients smoked 21–40 p/y (32.4%), 17 patients smoked 41–60
p/y by (14.5%) and 10 patients smoked more than 60 p/y (12.9%).
Of four patients exact calculation of p/y was not possible. Mean of
p/y was 36.5 for all NSCLC patients, 43.9 for the SCC-, and 23.5
for AC-subgroup.
SCLC-group
Forty patients with small cell lung cancer were included. As
common for SCLC, this group consisted of 35 males and ﬁve
females (gender-ratio: 7.0). Patients age ranged from 44–84, the
mean age was 63.3. One patient was not classiﬁed as a current
or former smoker. Two patients (5.0%) had not smoked more than
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a Group characteristics
Control group Lung cancer group
Matched controls
Population
(n=123)
Matched NSCLC
(n=77)
Matched SCLC
(n=40)
NSCLC
(n=77)
SCLC
(n=40)
SCC
(n=40)
AC
(n=26)
Male/Female 0.98 8.7 14.5 8.7 14.5 10.7 10.5
Age (range) 32.2
(20–62)
65.4
(42–82)
63.3
(44–84)
65.4
(42–82)
63.3
(44–84)
65.4
(34–82)
65.6
(42–81)
Never/Light smokers n (%) 69 (56.1) 9 (11.7) 1 (2.5) 9 (11.7) 1 (2.5) 2 (5.0) 6 (23.1)
Former smokers n (%) 9 (7.0) 11 (14.3) 12 (30.0) 11 (14.3) 12 (30.0) 5 (12.5) 5 (19.2)
Current Smokers n (%) 45 (36.0) 57 (74.0) 27 (67.5) 57 (74.0) 27 (67.5) 33 (82.5) 15 (57.7)
Table 1b Pack years (p/y) smoked by current or former smokers
n NSCLC (%) SCLC (%) SCC (%) AC (%)
11–20 p/y 10 (12.9) 2 (5.0) 2 (5.0) 6 (23.0)
21–40 p/y 25 (32.4) 15 (37.5) 14 (35.0) 6 (23.0)
41–60 p/y 17 (14.5) 13 (32.5) 13 (32.5) 5 (19.2)
460 p/y 10 (12.9) 6 (15.0) 5 (12.5) 1 (3.8)
Unavailable 4 (3.4) 2 (5.0) 3 (7.5) 1 (3.8)
Mean pk/yr 36.5 43.8 43.9 23.5
NSCLC=Non small cell lung cancer, SCLC= Small cell lung cancer, SCC=Squamous cell carcinoma, AC=Adenocarcinoma.
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p/y and six patients (15.0%) smoked more than 60 p/y (Table
1A,B). Mean number of p/y was 43.8.
Matched controls (control)
For each of the above mentioned lung cancer patients a matched
control (regarding age, gender and smoking habits) was included.
These controls were taken from 600 patients who had undergone
routine lung function tests in the Department of Internal Medicine
and had no history or symptoms of respiratory disease. Smoking
habits are matched to the lung cancer patients by classiﬁcation in
smoking more than 10 pack years as smokers and smoking less
or never smokers as low smokers. Of these 117 patients, 100
(85.4%) had coronary heart disease, four (3.4%) had sleep apnea,
three (2.5%) patients got surgery for cancer and 10 (8.5%) patients
suffered from other diseases. For the unmatched analysis the
NSCLC- and SCLC-matched control patients were grouped
together to create a non-matched control group. The group char-
acteristics of different subgroups are shown in Table 1A,B.
PCR
Whole EDTA-blood was used to prepare DNA using a kit provided
by Qiagen (Hilden, Germany). Mapping of the intron 4 variation
was performed using speciﬁc PCR. The nucleotide positions are
chosen according to Pilot-Matias et al (1989): 161 (TGTGTGTGA-
GAGTGAGGGTGTAAG; antisense, position 3174–3197) and 172
(CTGGTCATCGACTACTTCCA; sense position 2561–2581). PCR
was performed with 10 ng DNA as template, 0.2 units Taq poly-
merase (Boehringer Mannheim, Mannheim, Germany), 1.5 ml
buffer 1 (17.5 mM MgCl2) and buffer 2 (22.5 mM MgCl2)
106concentrated, (Boehringer Mannheim, Mannheim, Germany),
1 ml of speciﬁc primer (100 ng ml
71) 161 and 172, 1 ml dNTPs
(1.25 mM each dNTP).
The PCR were performed as hot-start PCR with following
cycling conditions: 30 cycles of 948C for 30 s, 598C for 1 min,
728C for 1 min, and a ﬁnal cycle of 5 min for 728C. As a size
marker we used cloned and sequenced intron 4 fragments as
described previously (Floros et al, 1995; Veletza et al, 1996). The
PCR-products and the clones were analysed by 1.5% agarose gel
electrophoresis and stained with ethidium bromide.
Statististical analysis
The statistical analysis was performed by means of the SPSS soft-
ware package (Version 9.0, SPSS Inc., Chicago, IL, USA).
Frequency of the SP-B variants in the respective groups
(control–group, population–control, NSCLC and SCLC) was
compared using the Chi-square and Fisher’s Exact Test methods.
Differences in the frequency of variations vs wild type were consid-
ered statistically signiﬁcant when a was 40.05 in Fisher’s Exact
Test. The 95% conﬁdential interval (95% CI) depicts the conﬁden-
tial interval of the given odds ratios.
RESULTS
Description of intron 4 variants in the groups under study
We analysed a polymorphism within intron 4 of the SP-B gene in
patients with lung cancer, their matched controls and healthy indi-
viduals. This large size gene variant is characterised by deletions or
insertions (Floros et al, 1995; Veletza et al, 1996), as shown sche-
matically in Figure 1. The wild type of intron 4 consists of 11
motifs (Floros et al, 1995), while the variants result from gain or
loss of motifs, consisting of a 20 bp conserved element, followed
by a variable number of CA-repeats. The break-point of deletions
or insertions does not occur in the conserved 20 bp sequences,
but within the CA-repeats. The analysis showed several variants
with deleted or inserted motifs that range from 78 to +7 motifs,
similar to those described before (Floros et al, 1995). Figure 2
depicts the invariant band with a size of about 600 bp (lanes 5
and 6). The variant band is either smaller or larger. We used
cloned and sequenced DNA as size markers to deﬁne the common
deletions as type I or II, lacking 5 or 8 motifs, respectively. Lanes
1–4 in Figure 2 depict examples of type I or type II deletion
variants, respectively, and lanes 7–10 examples of variants with
different insertions.
The frequency of intron 4 variants differs among various
groups
The frequency of the intron 4 variants was analysed in 357 indivi-
duals divided in two control and two cancer patient groups.
Similar to the previous studies that demonstrated an association
between the SP-B intron 4 variants and acute respiratory failure
in chronic obstructive pulmonary disease (COPD) (Seifart et al,
2002) and respiratory distress syndrome (Floros et al, 1995) we
grouped both variants (deletions and insertions) together. The
presence of the variant allele in the population and control group
does not differ (9.4%, 13.0%, respectively). This frequency was
increased in the SCLC and NSCLC group (17.5%, 16.9%, respec-
tively) without reaching statistical signiﬁcance (Table 2).
However, with respect to the tumour histology of the NSCLC-
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EXON 4 EXON 5
Wild type 600 bp
Deletion type I
Deletion type II
       Insertion
+
Motifs
Figure 1 Intron 4 group variants. The invariant segment (with 11 motifs)
is approximately 600 bp. The two common deletion variants are described
here as type I and type II, and lack 5 or 8 motifs, respectively. The larger size
variants are characterised by insertion of several motifs.
600 bp
600 bp
M               1               2               3               4
5          6           7           8           9          10         M
Figure 2 Analysis of intron 4 PCR products by agarose gel electro-
phoresis. M=molecular weight markers, lanes 1–4 show the type II and
type I deletions respectively (lower bands). Lines 5 and 6 depict the invar-
iant band, lanes 7–10 depict variants with different insertions (7=+2 mo-
tifs, 8=+3 motifs, 9=+6 motifs, 10=+7 motifs).
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variants (25.0%) in patients with squamous cell lung cancer
(P=0.016 (Fisher’s Exact Test), P=0.012 (Chi Square), OR=3.2,
95%CI=1.24–8.28 for the matched controls) (Table 2). Because
the other histology subtypes showed very low frequencies (adeno-
carcinoma: 11.5%, large cell carcinoma 0.0%, other subtypes
0.0%, all together without SCC: 7.5%) it became evident that the
high frequency in the SCC patients is responsible for the increase
in the whole NSCLC group. Interestingly, of the three patients with
SP-B gene variants belonging to the subgroup of adenocarcinoma,
two were low smokers or never smokers and one smoked less than
20 p/y. In the subgroup of SCC mean p/y does not differ between
those with SP-B gene variants (43.5) and those with SP-B wild type
(43.9).
All samples which showed variant alleles were heterozygous,
carrying one variant and one invariant allele, except for two
samples, one from the SCLC group, one from the SCLC matched
control, that were homozygous for the smaller size variant (dele-
tion). The individual from the SCLC group carried both type I
and type II alleles, the others were homozygous for type II deletion.
Among the 47 individuals with variant alleles 23.4% (11) were due
to insertions and 76.5% (36) were due to deletions. There was no
signiﬁcant difference in the frequency of alleles with insertions or
with deletions among the different groups. From the 34 alleles with
heterozygous deletions, 18 corresponded to type I, and 16 to type
II deletions. Together these data indicate an association between
intron 4 variability and/or its ﬂanking loci with mechanisms that
enhance susceptibility to squamous cell carcinoma of the lung.
DISCUSSION
In the present case–control study we analysed the frequency of SP-
B intron 4 variants in patients with lung cancer and demonstrated
an increase of gene variants in lung cancer patients with a high
signiﬁcant difference in the frequency between healthy persons
and patients with squamous cell lung cancer. The data suggest an
association between mechanisms that enhance susceptibility to
squamous cell lung cancer and the SP-B gene variants.
A number of respiratory diseases related to pathophysiological
conditions of the airways have been associated with an increased
risk of lung cancer. Independent of smoking behaviour, family
history and occupational exposure, lung cancer risk is increased
in patients with limited airway ﬂow (Skillrud et al, 1986). Pulmon-
ary surfactant is essential for normal lung function and provides
several functions related to local airway conditions, such as
enhancement of mucocilliary clearance, improvement of airway
stability, encoating, deposition and retention of inhaled substances
and particles as well as interaction with infectious agents. We
focused our attention on surfactant protein B, because SP-B is
necessary for the formation of the active surface ﬁlm, it is essential
for life (Clark et al, 1995) and an association of SP-B variants with
acute respiratory failure in COPD was demonstrated (Seifart et al,
2002). Moreover, there is an association of reduced levels of SP-B
observed in heterozygous SP-B knockout mice (7/+) with lung
physiological abnormalities, decreased lung compliance and
increased residual lung volume (Clark et al, 1997), as well as high
susceptibility to oxidative lung injury (Tokieda et al, 1999).
In contrast to the alveolar surfactant that is produced by type II
pneumocytes, the source of airway surfactant is less clear. It is
likely that airway surfactant derives by local secretion and from
the alveolar region. Epithelial cells of the tracheobronchial tree of
the human have the capacity to produce SP-A, SP-B and SP-C
(Phelps and Floros, 1988). Interestingly, although SP-B is synthe-
sised by alveolar type II cells and bronchiolar epithelial cells,
recent studies indicate that the function of alveolar and bronchiolar
SP-B may differ (Lin et al, 1999b). The role of bronchiolar SP-B is
currently unknown, but bronchiolar SP-B can not substitute for the
function of alveolar SP-B.
The variability within intron 4 of the surfactant protein B gene
is caused by the gain or loss of motifs (Floros et al, 1995; Veletza et
al, 1996), consisting of a 20 bp conserved sequence followed by
various dinucleotide repeats (CA-repeats). Currently, it is not
known whether the intron 4 variability has an impact on SP-B gene
expression or regulation. Neither is it known whether the SP-B
locus itself or a linked gene contributes to squamous cell lung
cancer or may be related to enhanced cancer susceptibility.
However, because this variability results in large deletions or inser-
tions, likely these alterations may compromise splicing and/or SP-B
mRNA processing that in turn result in altered SP-B mRNA and/or
lower amounts or impaired SP-B protein function protein. Disrup-
tion of the surfactant ﬁlm and function has been demonstrated in
SP-B knock-out mice (Clark et al, 1995, 1997), thus changes in the
amount and/or the activity of SP-B may result in impaired func-
tion of surfactant. As it is known, cigarette smoking is strongly
associated with the development of COPD and lung cancer. Smok-
ing can induce alterations of the surfactant system (Finley and
Ladman, 1972; Low et al, 1978) and these alterations may be more
serious if the composition of the surfactant system is disturbed.
The carcinogenic process of lung cancer is driven by the interaction
of exogenous carcinogenic exposures and the cellular response,
including genetic DNA repair capacity. The internal dose of carci-
nogens, such as tobacco smoke, the clearance and local conditions
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Table 2 Frequency of gene variations in the groups under study
Wild type
n (%)
Variation
n (%)
(Deletion/Insertion)
P-value
(Variation)
Odds ratio
(95%CI)
Population n=123 107 (87.0)1 6 ( 13.0)
[12 (9.8)/4 (3.2)]
Match NSCLC n=77 70 (90.9)7 ( 9.1)
[6 (7.8)/1 (1.3)]
Match SCLC n=40 36 (90.0)4 ( 10.0)
[3 (7.5)/1 (2.5)]
NSCLC n=77 64 (83.1)1 3 ( 16.9)
[9 (11.7)/4 (5.2)]
P=0.122 1.957
(0.82–4.62)
SCC n=40 30 (75)1 0 ( 25.0)
[7 (17.5)/3 (7.5)]
P=0.012* 3.21
(1.24–8.28)
SCLC n=40 33 (82.5)7 ( 17.5)
[6 (15.0)/1 (2.5)]
P=0.165 2.044
(0.73–5.69)
NSCLC=Non-small cell lung cancer, SCLC=Small cell lung cancer, SCC=Squamous cell carcinoma.
n=number of individuals with gene variations, %=% gene variations of the given group, 95%CI=95%
conﬁdence limits.
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cancer, as it could be seen in p53 mutations (Suzuki et al, 1992;
Greenblatt et al, 1994). Two physiological functions of the bronch-
iolar surfactant might play an important role in the interaction of
carcinogenetic substances of the lung: The clearance of inhaled
particles or substances and their encoating by surfactant.
Particles deposited on to the alveolar and airway surfaces are
encoated with surfactant and displaced into the aqueous phase
toward the epithelium (Allegra et al, 1985; Schu ¨rch et al, 1990).
Surfactant has also been shown to enhance particle clearance by
accelerating cilliary beat frequency (Kakuta et al, 1991; Gerber et
al, 1995) and conditioning the viscosity of the mucus (Gerber et
al, 1995). Surfactant coating enhances phagocytosis of inhaled
particles (Stringer and Kobzik, 1996), and reduces the cytotoxity
of particles and free radical activity (Cifuentes et al, 1995). Further-
more, it has been shown to decrease genotoxicity of non-porous
particles, such as silica and asbestos (Liu et al, 1994) and exogen-
ous surfactant treatment improves sputum mucociliary
transportability and lung function in patients with chronic bron-
chitis (De Sanctis et al, 1994; Anzueto et al, 1997). Disturbance
of these functional properties may mediate local airway conditions
and result in prolonged exposure and impaired interaction with
carcinogens. Therefore, the individual variability in the response
to environmental mutagens may be related to local factors
mediated by surfactant function. This hypothesis might be
supported by the observation that the association between exogen-
ous exposure to carcinogens has been shown strongest for
squamous cell carcinoma of the lung (Breslow et al, 1954; Weiss
et al, 1972) and the relative risk with increasing duration of expo-
sure rise fastest in this type of lung cancer. But, as SCLC is also
related to tobacco smoke and other exogenous substances, the
differences in SP-B variants in SCC and SCLC might be due to
statistical reasons because of small groups. Otherwise it might be
due to the different cell type of origin and differences in developing
pathways, as SCC arises from progression of metaplasia and dyspla-
sia, while SCLC does not in the same way. Although characteristic
patterns of DNA changes are caused by exogenous mutagens in
both lung cancer types for several molecular genetic changes, such
as G-protein pathways and MYC genes, differences between SCC
and SCLC have been shown (Greenblatt and Harris, 1995).
Currently, it is not known why there is a different mutational spec-
trum in those cancer types. For adenocarcinoma, as this lung
cancer type is not strongly related to exogenous mutagens, the
SP-B frequency is similar to the controls. For the other types of
lung cancer derives from small numbers of individuals, the SP-B
frequency could not be evaluated.
In summary, following investigation of differences in the
frequency of the SP-B intron 4 variants among various control
and lung cancer groups, we observed an association between this
polymorphism and a subgroup of NSCLC, the squamous cell lung
cancer. Although further studies are needed to determine the
impact on protein expression, and to determine whether the SP-
B locus itself contributes to the disease, it suggests that these gene
variations are associated with mechanisms of enhanced lung cancer
susceptibility. The effects of smoking are undoubtedly predomi-
nant, but changes in airway conditions related to SP-B gene
variants or ﬂanking loci may work as confounding risk factors to
squamous cell carcinoma.
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